Copenhagen-based Traitomic raised a €20M Series A led by Sofinnova Partners to sell non-GM crop and microbe trait discovery beyond brewing, with Carlsberg still a shareholder.
Key Takeaways
- Traitomic closed a €20M (about $22M) Series A on 17 November 2026, led by Sofinnova Partners.
- It has delivered 116 traits to 47 customers across 32 organisms; valuation is undisclosed.
- Carlsberg keeps the FIND-IT IP and brewing rights; Traitomic holds an exclusive licence for all other uses.
Lead
Traitomic, the Copenhagen company that Carlsberg spun out to commercialise its non-GM trait screening technology, has raised a €20M Series A led by Sofinnova Partners. The round was announced on 17 November 2026 and is the company's first external investment since the spinout. Traitomic did not disclose the valuation.
Danish state investor EIFO, The Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures also took part. The money is earmarked for expansion in the US and Australia and for scaling commercial operations.
What Does Traitomic Actually Sell?
Traitomic sells trait discovery as a service: it finds useful natural genetic variants in plants and microbes without directly editing genes. Its platform, FIND-IT, screens conventionally bred populations for naturally occurring mutations, then verifies and delivers the result to the customer.
The method was developed at the Carlsberg Research Laboratory and published in Science Advances in 2022, using a library of roughly 500,000 barley plants. Turnaround is quick for established platforms. A trait on a known platform takes about one to two months, a new crop needs one seed-to-seed cycle, and bacteria take about a week.
The pitch is an alternative to gene-editing tools such as CRISPR. Traits found this way follow a conventional breeding pathway, which avoids the regulatory uncertainty attached to gene-edited and GM products in some markets.
How Much Commercial Traction Is There?
Traitomic has delivered 116 traits to 47 customers across 32 organisms, spanning seed, food, precision nutrition and biosolutions. Another 100 traits are in pre-commercial assessment. The team is about 30 people, with a customer base across Europe, the US, Australia, South East Asia and East Asia.
Crop work centres on legumes, oilseeds and specialty crops such as lupin, pea, bean, oat and canola. Requested traits include drought tolerance, disease resistance and improved input efficiency. Most delivered traits are still moving through customers' testing and commercialisation pipelines, though some microbial products are already on sale.
That last point matters for reading the round. Delivery counts show demand for the service, but revenue depends on customers bringing finished varieties to market, a process that takes years in seed. Traitomic no longer works on barley or with brewers, so the Carlsberg link is now ownership and licensing rather than customer revenue.
What Is the Relationship With Carlsberg Now?
Carlsberg retains ownership of FIND-IT and its brewing rights, while Traitomic holds an exclusive licence for every other application. Carlsberg's stake after the round is reported at between 33% and 50%, so the brewer remains a significant shareholder without controlling the company.
CEO and co-founder Gustav Hambraeus described the company as "like a little bit of a teenager" that now needs to "move out". Sara Sande, managing director and partner at EIFO, said the investor is already seeing demand from some of the world's largest companies.
Why Does the Regulatory Backdrop Matter?
Regulation is the main driver of demand for non-GM routes. The EU's revised rules on gene-edited plants are due to take effect in July 2028, and until then the status of such crops remains a constraint for European breeders. Other markets, including the US and Australia, apply different frameworks, which helps explain why those two are the first expansion targets.
A softer EU regime is also a risk for Traitomic. If gene-edited crops gain easier market access, the regulatory premium for non-editing methods could shrink. The company's counter is that finding the right genetic change is often more valuable than creating it, and that a conventional pathway remains acceptable to both regulators and buyers.
Who Competes With Traitomic?
Competition comes from gene-editing-led plant biotech firms such as Tropic, which works on gene-edited bananas, and trait developers such as Rainbow Crops. Large seed companies also run in-house mutation screening and breeding programmes. Traitomic's differentiator is a licensed, screening-first platform that works across crops and microbes alike.
The Series A is also notable for its size relative to the sector. A €20M first outside round, backed by a life-sciences specialist and a state investor, suggests investors see a services-plus-licensing model with early customers as fundable. The undisclosed valuation leaves open how much of that confidence is priced into the deal.
What Comes Next?
Traitomic plans to broaden its organism scope to mushrooms, algae and probiotic bacteria and to build end-to-end trait development capabilities. US and Australian expansion comes first. The test over the next two to three years is conversion: how many of the 100 pre-commercial traits become varieties or products that generate royalties.
Outlook
Traitomic enters its next phase with €20M, a licence to a screening platform proven on barley and a customer list already at 47. The open questions are valuation, the pace at which traits reach the market, and how the EU's 2028 gene-editing rules change the appeal of non-GM discovery.



